CD274 and neoplasm: Although PD-L1 and tumor mutation burden (TMB), are two of the most extensively studied predictive biomarkers for cancer immunotherapy (31–33), their predictive value in gauging patient responses to immunotherapy in HCC has been relatively limited (34, 35).